Can the NIH replace all private sector clinical R&D?

A paper by Proudman et al. (2024) finds that doing so would be extremely expensive. Including all preclinical, clinical and post-approval R&D activities, total annual costs to maintain the average lifecycle level of 49.4 approved drugs across all disease areas during the 2018–22 period was estimated to be $139.6 billion. Including only pre-launch costs, total…

Read More

UNFPA Funding and Kemp-Kasten: An Explainer

This fact sheet provides an overview of the history of the Kemp-Kasten amendment, which states that no U.S. funds may be made available to “any organization or program which, as determined by the president of the United States, supports or participates in the management of a program of coercive abortion or involuntary sterilization,” and examines…

Read More

Can Medicaid’s Popularity Shield It From the Budget Ax? 

Congressional lawmakers are facing tricky arithmetic as they hammer out a budget plan to finance President Donald Trump’s agenda.  Republicans need to free up roughly $4 trillion to pay for renewing Trump’s 2017 tax cuts, which expire at the end of the year. Trump has vowed not to touch the costliest government programs, including Medicare…

Read More